Valor Medical's Neucrylate AN device receives CE Mark approval for treating cerebral aneurysms

Valor Medical announced today that it has received CE Mark approval for Neucrylate AN for treating cerebral aneurysms.

Neucrylate AN is a liquid embolic device that is injected through a microinfusion catheter into the aneurysm.  When Neucrylate AN comes in contact with the blood in the aneurysm it immediately changes from a liquid into a porous, elastic, sponge like material.  Unlike conventional micro-coils used for treating cerebral aneurysms Neucrylate AN fills the entire aneurysm – regardless of its size or shape.  

Charles Kerber, M.D., founder and Chief Medical Officer stated, "Neucrylate AN will be another tool for treating cerebral aneurysms, especially those with wide necks and the larger aneurysms of complicated shape.  During the clinical trials the time to treat patients was reduced from hours to minutes, which should increase the surgery's safety, and certainly decreased the radiation dose."

"The CE Mark approval for Neucrylate AN in Europe is a major accomplishment for Valor Medical.  We look forward to beginning commercialization activities and will begin training physicians next month in Budapest, Hungary," said H. Clark Adams, Chief Executive Officer